You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 9,192,608


✉ Email this page to a colleague

« Back to Dashboard


Title:Morphine formulations
Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.
Inventor(s): Cuine; Alain (St. Fargeau-Ponthierry, FR), Hoarau; Didier (Claix, FR), Romain; Pauline (Saint Egreve, FR)
Assignee: BECTON DICKINSON FRANCE S.A.S. (Le Pont de Claix, FR)
Filing Date:May 18, 2015
Application Number:14/715,277
Claims:1. A method of reducing pain in a subject, comprising: administering to the subject an injectable pharmaceutical formulation comprising per mL (a) from about 2 mg to about 10 mg of morphine sulfate or a hydrate thereof; (b) sodium chloride; (c) a buffering agent in an amount which provides a molar ratio of morphine sulfate to the buffering agent from about 0.4 to about 1.3 and is in an amount sufficient to provide a pH of 5 to the formulation; (d) disodium edetate dihydrate; (e) calcium chloride dihydrate; and (f) water for injection.

2. The method of claim 1, comprising (a) from about 4 mg and 10 mg of morphine sulfate or a hydrate thereof; and (c) a buffering agent in an amount which provides a molar ratio of morphine sulfate to the buffering agent from about 0.4 to 0.8 and is in an amount sufficient to provide a pH of about 5 to the formulation.

3. The method of claim 1, wherein the buffering agent has anti-oxidative properties.

4. The method of claim 1, wherein the buffering system comprises citric acid monohydrate and sodium citrate dihydrate.

5. The method of claim 1, wherein the formulation is stable at 80.degree. C. for at least 14 days.

6. The method of claim 1, wherein the formulation is stable at 40.degree. C. and 75% Relative Humidity for at least three months.

7. The method of claim 1, wherein the formulation is stable at 25.degree. C. and 60% Relative Humidity for at least 12 months.

8. A method of reducing pain in a subject, comprising: administering to the subject an injectable pharmaceutical formulation comprising per mL: (a) from about 2 mg to about 10 mg of morphine sulfate pentahydrate; (b) from about 7 mg to about 9 mg of sodium chloride; (c) from about 2 mg to about 4 mg of sodium citrate dihydrate; (d) from about 0.7 to about 1.2 mg of citric acid monohydrate; (e) from about 0.1 to about 0.15 mg of disodium edetate dihydrate; (f) from about 0.04 to about 0.06 mg calcium chloride dihydrate; and (g) water for injection.

9. The method of claim 8, wherein the formulation comprises (a) about 2 mg morphine sulfate pentahydrate; (b) about 8.4 mg of sodium chloride; (c) about 2.3 mg of sodium citrate dihydrate; (d) about 0.74 mg of citric acid monohydrate; (e) about 0.111 mg of disodium edetate dihydrate; (f) about 0.053 mg calcium chloride dihydrate; and (g) water for injection.

10. The method of claim 8, wherein the formulation comprises (a) about 4 mg morphine sulfate pentahydrate; (b) about 8.4 mg of sodium chloride; (c) about 2.3 mg of sodium citrate dihydrate; (d) about 0.74 mg of citric acid monohydrate; (e) about 0.111 mg of disodium edetate dihydrate; (f) about 0.053 mg calcium chloride dihydrate; and (g) water for injection.

11. The method of claim 8, wherein the formulation comprises (a) about 5 mg morphine sulfate pentahydrate; (b) about 7.5 mg of sodium chloride; (c) about 3.45 mg of sodium citrate dihydrate; (d) about 1.11 mg of citric acid monohydrate; (e) about 0.111 mg of disodium edetate dihydrate; (f) about 0.053 mg calcium chloride dihydrate; and (g) water for injection.

12. The method of claim 8, wherein the formulation comprises (a) about 8 mg morphine sulfate pentahydrate; (b) about 7.5 mg of sodium chloride; (c) about 3.45 mg of sodium citrate dihydrate; (d) about 1.11 mg of citric acid monohydrate; (e) about 0.111 mg of disodium edetate dihydrate; (f) about 0.053 mg calcium chloride dihydrate; and (g) water for injection.

13. The method of claim 8, wherein the formulation comprises (a) about 10 mg morphine sulfate pentahydrate; (b) about 7.5 mg of sodium chloride; (c) about 3.45 mg of sodium citrate dihydrate; (d) about 1.11 mg of citric acid monohydrate; (e) about 0.111 mg of disodium edetate dihydrate; (f) about 0.053 mg calcium chloride dihydrate; and (g) water for injection.

14. A method of reducing pain in a subject, comprising: administering to the subject an injectable pharmaceutical formulation comprising: a) morphine, or a salt thereof, or a hydrate thereof; b) an isotonic agent c) a buffering agent with anti-oxidative properties; d) a chelating agent; e) a complement to a chelating agent; and (f) water.

15. The method of claim 14, wherein, the morphine, or a salt thereof, or a hydrate thereof, is selected from anhydrous morphine, morphine hydrochloride, morphine sulfate, morphine tartrate, morphine citrate, morphine acetate, morphine methobromide, morphine hydrobromide, morphine hydroiodide, morphine lactate and morphine bitartrate.

16. The method of claim 14, wherein the morphine, or a salt thereof, or a hydrate thereof, is selected from morphine sulfate pentahydrate or morphine hydrochloride.

17. The method of claim 14, wherein the isotonic agent is selected from sodium chloride, calcium chloride, potassium chloride, sodium bicarbonate, sodium lactate, Ringer's solution, dextrose, lactose, mannitol, glucose, glycerine, dextran, Normosol R, saline, Hartmann's solution, and mixtures and combinations thereof.

18. The method of claim 14, wherein the isotonic agent is sodium chloride.

19. The method of claim 14, wherein the buffering agent is a di-carboxylic or tri-carboxylic acid.

20. The method of claim 14, wherein the buffering agent is citric acid, iso citric acid, aconitic acid, trimesic acid, propane-1,2,3-tricarboxylic acid, fumaric acid, oxalic acid, maleic acid, malonic acid, glutaric acid, succinic acid or tartaric acid, or hydrates thereof.

21. The method of claim 14, wherein the chelating agent is selected from edetic acid, ethylene glycol tetraacetic acid, ethylenediamine, diethylene triamine pentaacetic acid, N-(hydroxyethyl) ethylenediaminetriacetic acid, aminotriacetic acid, 2,3-dimercapto-1-propanesulfonic acid, dimercaptosuccinic acid, dimercaprol, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid, salts and hydrates thereof.

22. The method of claim 14, wherein the chelating agent is edetic acid.

23. The method of claim 14, wherein the complement to chelating agent is a calcium salt.

24. The method of claim 14, wherein the complement to chelating agent is calcium chloride dihydrate.

25. The method of claim 14, wherein, the formulation provides a unit dose of morphine, or a salt thereof, or a hydrate thereof, in a concentration from about 2 mg/mL to about 15 mg/mL.

26. A method of reducing adverse effects of a injectable morphine pharmaceutical formulation comprising disodium edetate dihydrate, the method comprising the addition of calcium chloride dihydrate to the injectable morphine pharmaceutical formulation wherein the formulation comprises per mL: (a) from about 2 mg to about 10 mg of morphine sulfate or a hydrate thereof; (b) sodium chloride; (c) a buffering agent in an amount which provides a molar ratio of morphine sulfate to the buffering agent from about 0.4 to about 1.3 and is in an amount sufficient to provide a pH of 5 to the formulation; (d) disodium edetate dihydrate; (e) calcium chloride dihydrate; and (f) water for injection.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.